Overcoming Treatment Challenges for Tuberous Sclerosis Complex (TSC): SEGA and the Future of Seizure Management

Overcoming Treatment Challenges for Tuberous Sclerosis Complex (TSC): SEGA and the Future of Seizure Management

Overcoming Treatment Challenges for Tuberous Sclerosis Complex (TSC): SEGA and the Future of Seizure Management
Dr. Krueger discusses current and emerging strategies for treating and managing SEGA associated with TSC.

Available credits: 1.00

Time to complete: 60 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by the systemic growth of benign, noninvasive legions. SEGAs, which are slow-growing glioneural tumors that develop near the foramen of Monro, usually develop before the age of 20 years and represent a significant morbidity and mortality burden in children and adolescents with TSC.

    The current standard of treatment for symptomatic SEGA is surgical resection of lesions. Asymptomatic SEGAs with growth can be treated with either surgery or therapy with the mTOR inhibitor everolimus. Because mTOR inhibition is the first pharmacotherapeutic alternative to surgery, it is important that clinicians be educated about its benefits and applications, thereby potentially improving patient quality of life and survival. Additionally, Wang and colleagues noted, “Prompt identification and treatment of seizures is an important focus in the overall management of tuberous sclerosis complex patients.” Everolimus and cannabidiol are being studied for the management of TSC-associated seizures.

    Given the rarity of the disease, clinicians may not be fully aware of SEGA associated with TSC, its clinical manifestations and molecular basis, or the current guidelines for diagnosis and treatment. Similarly, clinicians may not be up to date about the emerging treatment strategies for SEGA or appreciate their utility for those with TSC. As new therapies are approved, clinicians must be prepared to confidently use these agents, especially in treating a disease such as TSC, where new approaches and tools are desperately needed to improve patient outcomes in all of the TSC-related clinical manifestations.

    This activity aims to close educational gaps and provide clinicians with up-to-date knowledge about current and emerging treatment strategies to make informed clinical choices to confidently treat and manage SEGA associated with TSC.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe the most updated consensus guidelines regarding the diagnosis and clinical management of SEGA associated with TSC
    • Assess the current and emerging treatment options and anticipated outcomes for TSC patients
    • Explain the mechanism of action of mechanistic target of rapamycin (mTOR) inhibitors and their rationale for use in TSC
    • Evaluate evidence from clinical trials regarding the efficacy, tolerability, and safety of mTOR inhibitors
    • Evaluate evidence from clinical trials regarding therapies for the management of seizures in patients with TSC
  • Target Audience

    This activity is intended for pediatricians, family physicians, neurologists, neurosurgeons, and other healthcare professionals who diagnose, treat, and/or manage patients with tuberous sclerosis complex.

  • Faculty Disclosure

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Darcy A. Krueger, MD, PhD, reported a financial interest/relationship or affiliation in the form of Research grant, Novartis Pharmaceuticals Corporation.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. The following planners and managers, Linda Gracie-King, MS; Jocelyn Timko; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.  Steven Roberds, PhD, reports a financial interest/relationship or affiliation in the form of Contracted Research: Novartis support of TSC Natural History Database Project.


  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians
    AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit JA4008106-0000-18-009-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information
    For information about the certification of this activity, please contact AXIS at info@axismeded.com

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Global Neurology Academy newsletters.
Comprehensive Neurology Education.

Better education for a better you.

* Required

Join the Global Neurology Academy of learners.
Registration is free and easy.

Register Now